recombinant thrombomodulin
Jump to navigation
Jump to search
Contraindications
- does not mitigate coagulopathy of sepsis or affect inflammation
Adverse effects
- results in more bleeding
More general terms
References
- ↑ Vincent JL, Francois B, Zabolotskikh I et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: The SCARLET randomized clinical trial. JAMA. 2019;321(20):1993-2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31104069 https://jamanetwork.com/journals/jama/fullarticle/2733995